Tegal Corporation Reports Q1 Fiscal Year 2013 Financial Results

Tegal Corporation Reports Q1 Fiscal Year 2013 Financial Results

<0> Tegal CorporationChristine Hergenrother, 707-763-5600VP & CFO </0>

Tegal Corporation (NASDAQ: TGAL) today announced financial results for the First Quarter Fiscal Year 2013, which ended June 30, 2012.

Subsequent to the end of Q1, FY 2013, Tegal announced the closing of a transaction to acquire CollabRx, Inc., a cloud-based genomic information company that enables physicians to take into account a tumor's genetic profile when considering targeted therapies in patient-specific cancer treatments. The Chief Executive Officers of the two constituent companies, Thomas Mika of Tegal and James Karis of CollabRx, plan to serve as co-CEOs of the combined, publicly traded company, with headquarters in San Francisco, CA. Mr. Mika remains Chairman of the combined company. In connection with the closing, Mr. Karis was also appointed to Tegal’s Board of Directors. Tegal will continue to operate under its current name and ticker symbol for the time being, but plans to seek stockholder approval at its upcoming annual meeting on September 25, 2012 for an amendment to its Certificate of Incorporation, changing its corporate name to CollabRx, Inc.

Tegal subsequently announced that its CollabRx, Inc., subsidiary signed an exclusive license agreement to provide a version of its proprietary Therapy Finder™ tool to , Everyday Health, Inc.'s rapidly growing online site. Everyday Health reports that 96% of oncologists are served by , which had over 1.6 million unique visitors in June 2012, according to comScore. The CollabRx tool leverages recent dramatic increases in tumor genetic data, which in turn has resulted in a parallel increases in the development of cancer therapies that target specific genetic profiles. is a free service provided by to help physicians choose well for their patients. Everyday Health and will offer sponsorships and lead generation tools to major healthcare companies in connection with this initiative. In addition to licence fees, a portion of the revenue generated by sponsorships is to be shared with CollabRx.

“The acquisition of CollabRx immediately establishes our company in a leading position in interpretive content and data analytics for genomics-based medicine, one of today’s most important digital markets,” said Thomas Mika, Tegal’s Chairman, President and Co-CEO. “We are now positioned to be a cloud-based information leader in one of the world’s most significant high-growth sectors. At the same time, we are providing information to enhance the medical treatment of patients throughout the world. We are extremely proud to embark on our new mission.”

Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words "anticipate," "believe," "estimate," "expect," "intend," "project" or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies, market acceptance of the Company's products and services, the Company’s exploration and execution of strategic alternatives. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company's periodic filings with the Securities and Exchange Commission.

Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. For 40 years, Tegal's process and equipment know-how has been incorporated in devices fabricated by some of the world's leading semiconductor and MEMS companies, including Tegal's one-time parent, Motorola. Now entering its fifth decade, Tegal has committed its future to the CollabRx vision of "Informing Next Generation Healthcare". Please visit us on the web at .

CollabRx is a recognized leader in "cloud-based" expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be found at .

The weighted average number of shares and the net (loss) income per share reflect a 1-for-5 reverse split effected by the Company on June 15, 2011

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.